Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $188000.0.

  • Collegium Pharmaceutical's Capital Expenditures fell 2295.08% to $188000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 3009.63%. This contributed to the annual value of $1.7 million for FY2024, which is 25835.14% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Capital Expenditures stood at $188000.0 for Q3 2025, which was down 2295.08% from $65000.0 recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Capital Expenditures high stood at $940000.0 for Q4 2022, and its period low was $56000.0 during Q2 2023.
  • Over the past 5 years, Collegium Pharmaceutical's median Capital Expenditures value was $270000.0 (recorded in 2024), while the average stood at $354210.5.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 8851.44% in 2021, then soared by 38214.29% in 2024.
  • Over the past 5 years, Collegium Pharmaceutical's Capital Expenditures (Quarter) stood at $515000.0 in 2021, then skyrocketed by 82.52% to $940000.0 in 2022, then tumbled by 82.55% to $164000.0 in 2023, then soared by 247.56% to $570000.0 in 2024, then crashed by 67.02% to $188000.0 in 2025.
  • Its last three reported values are $188000.0 in Q3 2025, $65000.0 for Q2 2025, and $798000.0 during Q1 2025.